Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

MRK's decision to discontinue the development of two cancer drugs follows a series of setbacks in multiple late-stage studies ...

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

Merck halts vibostolimab and favezelimab trials due to efficacy results, prioritizing its oncology pipeline while the FDA ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...